Deep search
Search
Images
Videos
Maps
News
Shopping
Copilot
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the latter part of the year.
Bristol Myers CEO says new drug Cobenfy effective in schizophrenia, CNBC reports
Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older
Bristol Myers Squibb CEO describes new drug for treating schizophrenia
Bristol Myers Squibb CEO Chris Boerner described Cobenefy, a new drug to treat schizophrenia and may also help with bipolar disorder and Alzheimer’s disease.
Bristol Myers Says New Schizophrenia Drug Off to Strong Start
Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, in an early sign that its $14 billion purchase of Karuna Therapeutics is paying off.
Hosted on MSN
33m
FDA beats EMA to most approved new drugs in 2024
On 15 January, the two agencies released respective lists of medicines approved last year. The FDA approved 50 novel drugs ...
KOMU
1d
FDA approves first new schizophrenia drug in more than 30 years
The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.
2d
Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...
BioSpace
4d
5 Novel FDA Approvals Notched in 2024
Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...
CNBC on MSN
9d
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...
1d
AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?
AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?
3h
on MSN
Coventry must be 'more productive' in transfer window
Not too much should be read into 33-year-old Coventry-born forward Jamie Paterson training with The Sky Blues, with Lampard ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Coventry City
Bristol-Myers Squibb
Frank Lampard
Sheffield United F.C.
Feedback